Gina Mazzariello - Aug 15, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Aug 15, 2023
Transactions value $
-$128,686
Form type
4
Date filed
8/17/2023, 04:35 PM
Previous filing
May 19, 2023
Next filing
Feb 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Sale -$129K -6.16K -11.16% $20.88 49.1K Aug 15, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2023.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.41 to $21.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.